Metabolic imaging in myocardial ischemia and heart failure

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 2, 2010, Pages 168-176

  Knuuti, J ^a   Tuunanen, H ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Heart diseases; Heart failure, congestive; Imaging; Ischemia

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ACETIC ACID C 11; ADENOSINE TRIPHOSPHATE; AMMONIA N 13; CARBON 11; COPPER 62; COPPER 64; CREATINE PHOSPHATE; DIACETYL BIS( N4 METHYLTHIOSEMICARBAZONE) COPPER 62; DIACETYL BIS( N4 METHYLTHIOSEMICARBAZONE) COPPER 64; FATTY ACID; FLUORINE DERIVATIVE; FLUORO 6 THIAHEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; LACTIC ACID C 11; OXYGEN 15; PALMITIC ACID C 11; RADIOPHARMACEUTICAL AGENT; SEMICARBAZONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG METABOLISM; ECHOCARDIOGRAPHY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; HYPOXEMIA; ISCHEMIC HEART DISEASE; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION POTENTIAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77958604007     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.
2. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767-74.
3. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
4. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003;41:293-9.
5. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-36.
6. Camici P, Ferrannini E, Opie L. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Progr Cardiovasc Dis 1989;32:217-38. (Pubitemid 19274897)
7. Opie LH. Effects of regional ischemia on metabolism of glucose and fatty acids: relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia. Circ Res 1976;38(Suppl I):I-51-I-74.
8. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122:795-801.
9. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-51.
10. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009;54:1637-46.
11. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J Nucl Med 2001;42:55-62.
12. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271-7.
13. Tuunanen H, Engblom E, Naum A, Scheinin M, Nagren K, Airaksinen J et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006;12:644-52.
14. th edition. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004. p. 308-25, 331.
15. Essop F, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004;25:1765-8.
16. Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005;112:3218-21.
17. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
18. Herrero P, Sharp TL, Dence C, Haraden BM, Gropler RJ. Comparison of 1-(11)C-glucose and (18)F-FDG for quantifying myocardial glucose use with PET. J Nucl Med 2002;43:1530-41.
19. Takala TO, Nuutila P, Pulkki K, Oikonen V, Gronroos T, Savunen T et al. 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging 2002;29:1617-22.
20. Bergmann SR. Imaging of myocardial fatty acid metabolism with PET. J Nucl Cardiol 2007;14(3 Suppl):S118-24.
21. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996; 37:1723-30.
22. Biswas S K, Sarai M, Hishida H, Ozaki Y. 123I-BMIPP fatty acid analogue imaging is a novel diagnostic and prognostic approach following acute myocardial infarction. Singapore Med J 2009;50: 943-8.
23. Inaba Y, Bergmann SR. Prognostic value of myocardial metabolic imaging with BMIPP in the spectrum of coronary artery disease: A systematic review. J Nucl Cardiol 2010;17:61-70.
24. Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-98.
25. Klein LJ, Visser FC, Knaapen P, Peters JH, Teule GJ, Visser CA et al. Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med 2001;28:651-68.
26. Sorensen J, Andren B, Blomquist G, Stahle E, Langstrom B, Hedenstierna G. The central circulation in congestive heart failure non-invasively evaluated with dynamic positron emission tomography. Clin Physiol Fund Imag 2006;26:171-7.
27. Iida H, Rhodes CG, Araujo LI, Yamamoto Y, de Silva R, Maseri A et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Circulation 1996;94:792-807.
28. Beanlands RS, Armstrong WF, Hicks RJ, Nicklas J, Moore C, Hutchins GD et al. The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. J Nucl Cardiol 1994;1:3-16. (Pubitemid 24257825)
29. He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation 2003;108:1208-13.
30. Abbott BG, Liub Y-H, Arrighi JA. [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia. Nucl Med Commun 2007;28:89-94.
31. Dou K-F, Yang M-F, Yang Y-J, Jain D, He Z-X. Myocardial 18F-FDG Uptake After Exercise-Induced Myocardial Ischemia in Patients with Coronary Artery Disease. J Nucl Med 2008;49:1986-91.
32. Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE et al. Metabolic imaging with beta-methyl-p4(123)I)-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005;112:2169-74.
33. Nakamura A, Momose M, Kondo C, Nakajima T, Kusakabe K, Hagiwara N. Ability of 201T1 and 123I-BMIPP mismatch to diagnose myocardial ischemia in patients with suspected coronary artery disease. Ann Nucl Med 2009;23:793-8.
34. Biswas SK, Sarai M, Yamada A, Toyama H, Motoyama S, Harigaya H et al. The washout rate of 123I-BMIPP and the evolution of left ventricular function in patients with successfully reperfused ST-segment elevation myocardial infarction: comparisons with the echocardiography. Int J Cardiovasc Imaging 2010;26:155-64.
35. Lapi SE, Vollerb TF, Welch MJ. Positron Emission Tomography Imaging of Hypoxia. PET Clin 2009;4:39-47.
36. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60.
37. Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R et al. Delineation of hypoxia in canine myocardium using PET and coppe(II)-diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med 2002;43:1557-69.
38. Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med 2001;15:293-6.
39. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M et al. Reversibility of cardiac wallmotion abnormalities predicted by positron emission tomography. N Engl J Med 1986;314:884-8. (Pubitemid 16126116)
40. Knuuti MJ, Saraste M, Nuutila P, Harkonen R, Wegelius U, Haapanen A et al. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127(4 Pt 1): 785-96.
41. Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176-9.
42. Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity and predictive accuracies of various non-invasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001;26:141-88. (Pubitemid 32221097)
43. Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC et al., Schwarz ER, Vanoverschelde JL, van der Wall EE, Wijns W; Study Group of the European Society of Cardiology. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004;25:815-36.
44. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
45. Beanlands RS, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002;40:1735-43.
46. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-12.
47. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000;278:H1345-51.
48. Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002;39:718-25. (Pubitemid 34158171)
49. Xu KY, Zweier JL, Becker LC. Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport. Circ Res 1995;77:88-97.
50. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114:2130-7.
51. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy. Circulation 2008;118:1250-8.